- |||||||||| Avastin (bevacizumab) / Roche
Journal: Updates in the Management of Recurrent Glioblastoma Multiforme. (Pubmed Central) - Jul 1, 2022 Initiation date: May 2022 --> Dec 2022 Although recurrent glioblastoma remains a fatal disease with universal mortality, the literature suggests that a subset of patients may benefit from maximal treatment efforts.
- |||||||||| VBI-1901 / VBI Vaccines
Enrollment change, Trial completion date, Trial primary completion date: Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects (clinicaltrials.gov) - Jul 1, 2022 P1/2, N=98, Active, not recruiting, Although recurrent glioblastoma remains a fatal disease with universal mortality, the literature suggests that a subset of patients may benefit from maximal treatment efforts. N=38 --> 98 | Trial completion date: Mar 2022 --> Aug 2025 | Trial primary completion date: Mar 2022 --> Jul 2025
- |||||||||| carmustine / Generic mfg.
Trial completion date, Trial primary completion date: Therapeutic Targeting of Sex Differences in Pediatric Brain Tumor Glycolysis (clinicaltrials.gov) - Jun 28, 2022 P=N/A, N=15, Recruiting, N=38 --> 98 | Trial completion date: Mar 2022 --> Aug 2025 | Trial primary completion date: Mar 2022 --> Jul 2025 Trial completion date: May 2032 --> May 2034 | Trial primary completion date: May 2024 --> May 2026
- |||||||||| Amplimexon (imexon) / Amplimed Corp, SG 2000 / AstraZeneca
Biomarker, Journal, Tumor Mutational Burden, IO biomarker, Pan tumor: A pan-cancer analysis identifies HDAC11 as an immunological and prognostic biomarker. (Pubmed Central) - Jun 8, 2022 HDAC11 is also associated with hallmark pathways, including epithelial mesenchymal transition, IL-6/JAK/STAT3, and allograft rejection pathways. Overall, we provide clues regarding the key role of HDAC11 in multiple cancers.
- |||||||||| carboplatin / Generic mfg., vincristine / Generic mfg.
Journal: Carboplatin Plus Vincristine as an Alternative Chemotherapeutic Scheme in Patients With Glioblastoma. (Pubmed Central) - Jun 4, 2022 In this study, we aimed to determine the survival rates in patients treated with C/V, by comparing our findings with treatments based on temozolomide (TMZ), and to explore a possible relationship with the methylation status of the methylguanine methyltransferase (MGMT) promoter in patients with glioblastoma (GB)...Conclusions Based on our findings, C/V offers an accessible and effective alternative treatment when the TMZ-based scheme is not accessible, providing higher rates of OS compared to patients without chemotherapy management. The methylation status of the MGMT promoter is a significant prognostic factor, resulting in higher survival rates among patients when it is methylated.
- |||||||||| Gliadel Wafer (carmustine implant) / Eisai, Arbor Pharma
Journal: A numerical study of the distribution of chemotherapeutic drug carmustine in brain glioblastoma. (Pubmed Central) - May 31, 2022 Moreover, the simulation approach can be used as the guild for remedy optimization and dynamic analysis of other drugs (paclitaxel) for tumor treatment in the clinic. This mathematical model has wide applications about drug release in multiple dosage forms, such as long sustained release microspheres, oral extended release hydrophilic matrix tablets, hydrogel, and sustained release topical rings.
- |||||||||| Talzenna (talazoparib) / Pfizer, Lynparza (olaparib) / Merck (MSD), AstraZeneca
Journal, PARP Biomarker: XRCC1 counteracts PARP poisons, Olaparib and Talazoparib, and a clinical alkylating agent, Temozolomide, by promoting the removal of trapped PARP1 from broken DNA. (Pubmed Central) - May 25, 2022 We reveal the synthetic lethality of the XRCC1 mutation, but not POLβ , with Olaparib and Talazoparib, indicating that XRCC1 is a unique BER factor in suppressing toxic PARP1/SSB complex and can suppress even when PARP1 catalysis is inhibited. In conclusion, XRCC1 suppresses the PARP1/SSB complex via PARP1 catalysis-dependent and independent mechanisms.
- |||||||||| carmustine / Generic mfg.
Journal: Supramolecular Hydrogel Based Post-Surgical Implant System for Hydrophobic Drug Delivery Against Glioma Recurrence. (Pubmed Central) - May 25, 2022 Model hydrophobic drugs carmustine and curcumin entrapment propelled glioma cells into apoptosis-based death evaluated by in vitro cytotoxicity assays and Western blot...PCL-PEG soft gel-based implant is malleable compared with rigid wafers used as implants, thus providing larger surface area contact. This stable, biocompatible, supramolecular gel without external crosslinking can find wide applications by interchanging formulation of various hydrophobic drugs to ensure and increase site-specific delivery, avoiding systemic circulation.
- |||||||||| Mustargen (mechlorethamine) / Recordati
Trial completion date, Trial primary completion date, Metastases: SHARON: A Clinical Trial for Metastatic Cancer With a BRCA or PALB2 Mutation Using Chemotherapy and Patients' Own Stem Cells (clinicaltrials.gov) - May 20, 2022 P1, N=10, Recruiting, This stable, biocompatible, supramolecular gel without external crosslinking can find wide applications by interchanging formulation of various hydrophobic drugs to ensure and increase site-specific delivery, avoiding systemic circulation. Trial completion date: Dec 2023 --> May 2024 | Trial primary completion date: Dec 2023 --> May 2024
- |||||||||| OUTCOMES OF REDUCED DOSE TEAM (THIOTEPA, ETOPOSIDE, CYTARABINE, MELPHALAN) PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANTATION FOR HODGKIN AND NON-HODGKIN LYMPHOMA: A MONOCENTRIC EXPERIENCE () - May 13, 2022 - Abstract #EHA2022EHA_2393;
Two patients underwent allogeneic SCT with a median time after auto-SCT of 11 and 23 months, respectively. The 100-day and one-year non-relapse-mortality (NRM) was 2.5% [95% CI 0.2-11]. Eight patients died: one 5 days after auto-SCT due to septic shock; 5 due to disease progression and 2, after disease relapse, due to suicide and cerebral hemorrhage, respectively. At last follow-up, 29 patients (81%) were in CR. With a median follow-up of 21 (range3-77) months, 2-year progression-free and overall survival were 59%[95% CI 38-75] and 81% [95% CI 74-88]. Median PFS was 14 months (range 0-77) and median OS was 17 months (range 0-77). Conclusion Reduced TEAM is a feasible and valid regimen prior to auto-SCT, with low toxicity and NRM and acceptable survival rates.
- |||||||||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche, Matulane (procarbazine hydrochloride) / Leadiant Biosci
Impact of systemic therapy regimen on survival of PCNSL. (Available On Demand; 408) - Apr 28, 2022 - Abstract #ASCO2022ASCO_4425; Incorporation of R into 1st line therapy was associated with worse OS. Survival remained poor throughout the study period, underscoring importance of further innovation.
- |||||||||| Venclexta (venetoclax) / Roche, AbbVie, Walter and Eliza Hall Institute
Trial completion date, Trial primary completion date, Combination therapy: Venetoclax in Combination With BEAM Conditioning Regimen for ASCT in Non-Hodgkin Lymphoma (clinicaltrials.gov) - Apr 26, 2022 P1, N=30, Suspended, Survival remained poor throughout the study period, underscoring importance of further innovation. Trial completion date: Mar 2023 --> Aug 2023 | Trial primary completion date: Mar 2022 --> Aug 2022
- |||||||||| Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Enrollment change, Trial completion date, Trial primary completion date: Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases (clinicaltrials.gov) - Apr 25, 2022 P2, N=80, Recruiting, Trial completion date: Mar 2023 --> Aug 2023 | Trial primary completion date: Mar 2022 --> Aug 2022 N=40 --> 80 | Trial completion date: Dec 2027 --> Jun 2033 | Trial primary completion date: Mar 2026 --> Jan 2028
- |||||||||| Mozobil (plerixafor) / Sanofi, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Experience of delivering MATRIX chemotherapy and autologous stem cell transplant forCentral room 3- 4nervous system lymphoma within South East Scotland () - Apr 25, 2022 - Abstract #BSH2022BSH_218; Four cycles of MATRix (methotrexate, cytarabine, thiotepa, rituximab) followed by autologous stem cell transplant (ASCT) with carmustine/thiotepa conditioning is now standard of care in fit patients...Two (13%) failed to mobilise, both after four cycles MATRIX and also failed plerixafor harvest...In summary, four cycles MATRIX followed by ASCT is deliverable in majority with improved outcomes compared to historical data. Responses in relapse post-treatment remain disappointing despite use of ibrutinib and lenalidomide.
- |||||||||| Epidaza (chidamide) / Chipscreen, Meiji Seika, Eisai, HUYA Bioscience, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Journal: Modified conditioning regimen with chidamide and high-dose rituximab for triple-hit lymphoma. (Pubmed Central) - Mar 16, 2022 High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (auto-HSCT) is considered to be one of the recommended treatment options. Here, we reported 3 THL patients received carmustine, etoposide, cytarabine and cyclophosphamide (BEAC) combined with chidamide and high-dose rituximab conditioning regimen and found that this conditioning showed good efficacy and tolerance without increase of adverse events.
|